Helping mothers and babies, from conception to birth
At Ferring, we are committed to helping people become parents and to keeping mothers and babies healthy, from conception to birth. Over one third of our research and development investment goes towards finding innovative treatments in reproductive medicine and maternal health. We are also passionate about making a difference to people’s health and quality of life through our work in gastroenterology and urology.
Believing in the power of research
Each of us at Ferring contribute to providing innovative solutions to help people live better lives. We devote significant research and development investment to new therapeutics, life cycle management and next generation healthcare solutions.
Join us
At Ferring Pharmaceuticals we highly value an attractive working environment that motivates our employees and stimulates the creative abilities and initiative of both individuals and teams. With more than 7,000 employees in over 50 countries, we are able to draw upon a large multicultural setting to enrich the work of our staff on all levels.
Helping people live better lives
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years.
News
Ferring bolsters global gene therapy supply chain with European manufacturing facility
-This milestone represents significant progress in Ferring’s manufacturing capabilities to meet anticipated growth in demand for Adstiladrin® (nadofaragene firadenovec-vncg), a gene therapy for people with non-muscle invasive bladder cancer (NMIBC). With bladder cancer now the ninth most…
Ferring demonstrates effectiveness of a treat-to-target approach in mild-to-moderate ulcerative colitis in first major study
-OPTIMISE study found a treat-to-target (T2T) management strategy in people with mild-to-moderate ulcerative colitis (M2M UC) being treated with 5-aminosalicylic acid (5-ASA; mesalazine) utilising faecal calprotectin (FC) home monitoring over 12 months achieved…
Dr. Michael Rosenblatt joins Ferring Pharmaceuticals’ Board of Directors
-Ferring appoints Dr Michael Rosenblatt to its Board of Directors. Dr Rosenblatt has served as a founding scientist, scientific advisory board member, and director of several biopharmaceutical companies. Jan Lundberg is stepping down from his role of Chairman of…
